Influence of clindamycin on derepression of beta-lactamases in Enterobacter spp. and Pseudomonas aeruginosa.

Antimicrobial Agents and Chemotherapy
C C SandersR V Goering

Abstract

Previous studies in this and other laboratories have shown that derepression of beta-lactamases in strains of Enterobacter and Pseudomonas spp. is responsible for the rapid development of resistance to a variety of beta-lactam antibiotics. The purpose of the current study was to evaluate the effects of clindamycin on derepression of beta-lactamases in these two genera. In tests with four strains of each genus, clindamycin diminished derepression in one isolate of each genus and completely prevented derepression in a second Enterobacter isolate (strain 55). Additional tests with strain 55 revealed that other inhibitors of macromolecular synthesis did not completely prevent derepression of beta-lactamase when tested at concentrations that did not inhibit replication. However, clindamycin did not affect synthesis of beta-lactamase that was constitutively produced in a mutant of this strain (55M). It also did not inhibit derepression of beta-galactosidase in either strain 55 or 55M. Clindamycin did not diminish the bactericidal effects of beta-lactam antibiotics against Enterobacter or Pseudomonas spp. However, it enhanced the bactericidal activity of cefamandole against strain 55. These in vitro effects of clindamycin on strain 55...Continue Reading

References

Jun 1, 1979·Antimicrobial Agents and Chemotherapy·C C Sanders, W E Sanders
Apr 1, 1979·Antimicrobial Agents and Chemotherapy·P M Waterworth, A M Emmerson
Sep 1, 1977·The Journal of Antimicrobial Chemotherapy·T SacksJ Stessman
Jun 1, 1975·Antimicrobial Agents and Chemotherapy·J MichelT Sacks
May 16, 1980·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·M Cole
Jan 1, 1982·The Journal of Infectious Diseases·C C SandersW E Sanders
Jan 1, 1983·Antimicrobial Agents and Chemotherapy·T D Gootz, C C Sanders
Apr 1, 1981·Antimicrobial Agents and Chemotherapy·N A KuckM Forbes
Mar 1, 1983·The Journal of Infectious Diseases·C C Sanders
Jun 1, 1982·Antimicrobial Agents and Chemotherapy·R V GoeringW E Sanders
Oct 1, 1980·Journal of Clinical Microbiology·D G Beckwith, J A Jahre
Apr 1, 1982·Antimicrobial Agents and Chemotherapy·M F LampeJ C Sherris
Jun 1, 1982·Antimicrobial Agents and Chemotherapy·C C SandersR V Goering
Jun 1, 1982·Antimicrobial Agents and Chemotherapy·V I AhonkhaiU Bancroft

❮ Previous
Next ❯

Citations

Aug 1, 1987·European Journal of Clinical Microbiology·D M Livermore
Oct 1, 1984·Antimicrobial Agents and Chemotherapy·D H WuP E Conley
Jul 1, 1986·Antimicrobial Agents and Chemotherapy·A OkabeH Hayashi
Apr 1, 1988·Clinical Microbiology Reviews·G M Eliopoulos, C T Eliopoulos

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.